ReviewDiscover nano2026
Current status of extracellular vesicle technology in industrialization and commercialization.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are nanovesicles secreted by most cells types that play essential roles in intercellular communication and molecular exchange. Due to their diverse cellular origins, small molecule size, high stability, excellent biocompatibility, and cell targeting, EVs have emerged as promising tools for disease diagnosis and therapy, targeted drug delivery, and regenerative medicine. This review provides an overview of the biochemical characteristics, production methods, and industrial development of EVs based on patent filings and registered clinical trials related to EVs from 2015 to 2024. We further analyze major translational bottlenecks hindering the commercialization of EVs, emphasizing challenges related to batch-to-batch reproducibility, methodological standardization, manufacturing scalability, and regulatory pathway clarity. Finally, we highlight new engineering approaches including 3D hollow-fiber bioreactors, microfluidic isolation platforms, and genetic bioengineering that hold significant potential to address current limitations in EV manufacturing and clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.